Acuitas Investments LLC Boosts Stake in Kodiak Sciences Inc. (NASDAQ:KOD)

Acuitas Investments LLC raised its position in Kodiak Sciences Inc. (NASDAQ:KOD) by 59.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 234,092 shares of the company’s stock after buying an additional 87,043 shares during the period. Acuitas Investments LLC’s holdings in Kodiak Sciences were worth $712,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in KOD. Acadian Asset Management LLC lifted its position in shares of Kodiak Sciences by 253.6% during the third quarter. Acadian Asset Management LLC now owns 1,636,621 shares of the company’s stock worth $2,945,000 after purchasing an additional 1,173,832 shares during the last quarter. Silverarc Capital Management LLC acquired a new stake in shares of Kodiak Sciences in the third quarter valued at approximately $2,006,000. Newtyn Management LLC increased its stake in shares of Kodiak Sciences by 62.5% in the third quarter. Newtyn Management LLC now owns 1,608,694 shares of the company’s stock valued at $2,896,000 after purchasing an additional 618,991 shares during the period. Monaco Asset Management SAM increased its stake in shares of Kodiak Sciences by 129.5% in the third quarter. Monaco Asset Management SAM now owns 493,726 shares of the company’s stock valued at $889,000 after purchasing an additional 278,605 shares during the period. Finally, Marquette Asset Management LLC acquired a new stake in shares of Kodiak Sciences in the third quarter valued at approximately $54,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Kodiak Sciences Stock Performance

KOD traded up $0.08 during trading on Friday, hitting $3.27. The stock had a trading volume of 70,399 shares, compared to its average volume of 817,355. Kodiak Sciences Inc. has a 12 month low of $1.37 and a 12 month high of $9.80. The company has a 50 day simple moving average of $5.13 and a 200-day simple moving average of $3.67.

Kodiak Sciences (NASDAQ:KOD) last announced its earnings results on Thursday, March 28th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.27). As a group, analysts expect that Kodiak Sciences Inc. will post -4.31 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on KOD shares. UBS Group raised their price objective on shares of Kodiak Sciences from $3.00 to $5.00 and gave the company a “neutral” rating in a research note on Thursday, April 4th. Barclays raised their price objective on shares of Kodiak Sciences from $2.00 to $3.00 and gave the company an “underweight” rating in a research note on Monday, April 1st. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $5.50.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.